Vaccination Programme Launched to Combat Meningitis B Outbreaks
A vaccination programme offering protection against meningitis B will be made available to one million young people across England, Wales, and Scotland. This initiative follows concerns about the UK's largest and fastest growing meningitis B outbreak recorded this year in Kent, alongside two additional clusters identified in Weymouth, Dorset, and Reading, Berkshire.
The programme involves a two-dose vaccine regimen targeted at pupils currently in their final year of secondary school and individuals aged 18 to 25 who are beginning university or residential further education for the first time this autumn. Health officials emphasize that this effort aims to protect those at the highest immediate risk from meningococcal disease, which can lead to severe and life-threatening illness.
Case Highlight: The Tragic Loss of Aaron Mills
Aaron Mills, an 18-year-old from Kidderminster, Worcestershire, died from meningitis in January 2026. Aaron had recently commenced studies at John Moores University in Liverpool and was home for the Christmas holidays when he fell ill. Initially presenting with mild flu-like symptoms, he returned to bed on 30 December with a headache. Within thirty minutes, his family heard distressing screams from his room.
"His eyes were open but he was fitting and unresponsive, he didn't know we were there," Aaron's mother recounted to the BBC.
"When the hospital told us it was meningitis I was confused, because I thought Aaron had been vaccinated, and we checked and he was. But we didn't know until afterwards that there are different strains of meningitis," his father explained.
Currently, a different vaccine, the MenACWY vaccine, which covers other meningococcal strains, is routinely administered to teenagers aged 14. Aaron's family described the impact of his death as devastating.
"The impact this has had on the family and friends is horrific. The pain is unbearable."
Transmission and Risk Factors
Meningitis B bacteria spread through close contact, including kissing, sharing vaping devices or drinks, and living in close quarters with an infected person. UK health authorities note that individuals aged 18 or those entering university for the first time face a higher risk due to increased social mixing and shared accommodation environments.
Vaccination Details and Availability
The one-off MenB vaccination programme requires two doses administered at least 28 days apart for optimal protection.
In England, vaccinations will be offered in July and August through community pharmacies, with no requirement to attend the same pharmacy for both doses. Year 13 students will receive direct contact via the NHS app, text, email, or letter, depending on health records. Meanwhile, under-25s starting university for the first time can book appointments directly with pharmacies.
International students under 25 entering their first year of university are advised by the UK Health Security Agency (UKHSA) to receive their first dose before arriving for studies, where feasible.
In Wales, the vaccination programme will run from July to December. Individuals aged 17 to 18 will receive letters from health boards starting early July, while those aged 18 to 25 entering higher education will be required to contact their health board later in July.
Scotland’s programme will also commence in July. Northern Ireland plans to implement a similar programme in due course, according to UK health officials.
Government and Expert Statements
James Murray, Secretary of State for Health and Social Care in England, stated: "The Kent outbreak and recent clusters indicate a possible change to the way MenB affects people. While we assess the latest evidence, we are acting now to help protect young people at highest immediate risk as they enter university and residential colleges this autumn. By offering two doses of the jabs ahead of the academic year, we will help reduce the risk of serious illness and larger outbreaks of this horrendous disease."
The decision to implement this one-off programme follows the identification of "three rather unusual clusters of MenB disease" and concerns about a potential increase in meningococcal disease activity in coming years, according to Professor Shamez Ladhani of the UKHSA.
Details of Recent Outbreaks
In March 2026, an outbreak in Kent resulted in 21 confirmed cases of meningitis B, including two fatalities. This outbreak was unprecedented due to the high number of infections within a short timeframe.
Additionally, a cluster of three meningitis B cases among young people was reported in Weymouth in April 2026. In Reading, one death occurred, and three further cases were confirmed among students.
Professor Ladhani commented: "So far the number of cases this year is no different to the case numbers that we've seen in the last few years, but given that we are seeing these cases in young adults, action is being taken to protect those who are at highest risk immediately."
While investigations continue, one likely explanation for the unusual outbreak in Kent is the natural cyclical pattern of meningitis B, which alternates between years of low and high activity. Professor Ladhani noted that the UK has experienced a "honeymoon period" of 25 years of low activity, resulting in reduced exposure to the bacteria and potentially increased susceptibility among the population.
Vaccine Information and Impact
The Bexsero vaccine offered in this programme is routinely administered to babies and infants, with evidence indicating protection lasts at least six years. Data from the UK infant vaccination programme demonstrates approximately a 75% reduction in meningitis B disease incidence.
Vaccine experts are currently evaluating whether to expand the routine vaccination programme to include additional age groups.
Charity Response and Ongoing Awareness
Dr Tom Nutt of the charity Meningitis Now stated: "Today's announcement will be welcomed by all those who have fought for better protection for precious young lives. It represents real progress and has significant potential to prevent cases of meningitis. There is still more work to do to ensure everyone at risk is protected, including those already at university and younger teenagers. We will also continue to campaign for the MenB vaccination to become part of the UK's routine immunisation programme."
He added that while vaccination remains the best defence against meningitis, individuals should remain vigilant for signs and symptoms of the disease and seek urgent medical attention if concerned.
What Are the Symptoms?
